Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Cyclodextrin Ameliorates the Progression of Atherosclerosis via Increasing High-Density Lipoprotein Cholesterol Plasma Levels and Anti-inflammatory Effects in Rabbits

Wang, He, MS; Zhang, Xinwei, MS; Yu, Biao, MS; Peng, Xiaohuan, MS; liu, Ying, MS; Wang, Anbei, MS; Zhao, Dazhong, MS; Pang, Daxin, PhD; OuYang, Hongsheng, PhD; Tang, Xiaochun, PhD

Journal of Cardiovascular Pharmacology: May 2019 - Volume 73 - Issue 5 - p 334–342
doi: 10.1097/FJC.0000000000000660
Original Article
Buy
SDC

Abstract: To investigate the therapeutic effects of cyclodextrin on the development of atherosclerosis in rabbits, we evaluated the effects of (2-hydroxypropyl)-β-cyclodextrin (HPβCD) therapy on the organ coefficient, lipid profiles, inflammatory cytokines, and atherosclerotic plaques in rabbits fed a high-fat diet. Our results demonstrated that HPβCD therapy reduced plasma triglyceride levels and inflammatory cytokine levels but increased plasma high-density lipoprotein cholesterol levels. HPβCD therapy produced a significant decrease in the atherosclerotic lesion area and reduced macrophage and collagen content in the lesions. The expression levels of inflammatory genes in aortic plaques were significantly reduced by HPβCD treatment, but the expression of ATP-binding cassette (ABC) transporters A1 (ABCA1) and G1 (ABCG1) in aortic plaques and livers increased significantly. HPβCD therapy may produce additional antiatherosclerotic benefits likely via increasing high-density lipoprotein cholesterol levels.

Jilin Provincial Key Laboratory of Animal Embryo Engineering, College of Animal Sciences, Jilin University, Changchun, China.

Reprints: Xiaochun Tang, Jilin Provincial Key Laboratory of Animal Embryo Engineering, College of Animal Sciences, Jilin University, Changchun 130062, Jilin Province, China (e-mail: xiaochuntang@jlu.edu.cn).

Supported by the National Natural Science Foundation of China (Grant No. 31472053 and 31572345). The Program for JLU Science and Technology Innovative Research Team (JLUSTIRT, No. 2017TD-28), the Fundamental Research Funds for the Central Universities.

The authors report no conflicts of interest.

Received October 29, 2018

Accepted January 23, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.